Discordant humoral and T cell immune responses to SARS-CoV-2 vaccination in people with multiple sclerosis on anti-CD20 therapy

Sachin P. Gadani, Maria Reyes‐Mantilla, Larissa Jank, Samantha Harris, Morgan Douglas, Matthew D. Smith, Peter A. Calabresi, Ellen M. Mowry, Kathryn C. Fitzgerald, Pavan BhargavamedRxiv 2021 · DOI

Abstract

We identified a robust T cell response in individuals on anti-CD20 therapies despite a reduced humoral response to SARS-CoV-2 vaccination. Follow up studies are needed to determine if this translates to protection against COVID-19 infection.

Introduction

The COVID-19 pandemic presented a significant challenge for individuals with Multiple Sclerosis (MS), particularly those managed with disease-modifying therapies (DMTs). Specifically, anti-CD20 therapies (such as ocrelizumab and rituximab) and S1P-receptor modulators work by depleting or sequestering B cells. Since B cells are the primary drivers of antibody production, early clinical data indicated that these patients often failed to mount a robust "humoral" response to mRNA vaccines. This study sought to determine if the cellular arm of the immune system—the T-cell response—remained intact or perhaps even compensated for the lack of antibodies.

Methods

Researchers at the Johns Hopkins MS Center conducted a cross-sectional study of 101 participants who had completed their initial SARS-CoV-2 vaccination series (Pfizer, Moderna, or J&J). The cohort included 39 patients on anti-CD20 therapy, 16 on injectables, 16 on natalizumab, 14 on other oral therapies, 3 on fingolimod (an S1P modulator), and 14 on no therapy.

The team utilized two primary assays to evaluate the immune response:

  1. Humoral Response: An ELISA (enzyme-linked immunosorbent assay) measured IgG antibodies against the SARS-CoV-2 spike S1 glycoprotein.
  2. Cellular Response: A FluoroSpot assay was used to count interferon-gamma (IFN-γ) producing T cells. Peripheral blood mononuclear cells (PBMCs) were isolated and stimulated with peptide pools covering the spike protein to identify "spot forming cells" (SFCs).

Linear and logistic regression models were employed to compare these responses across DMT categories, adjusting for age, sex, and the timing of blood draws relative to vaccination.

Key Results

The Discordant Response

The study's most significant finding was a clear "discordance" between antibody and T-cell activity in patients on anti-CD20 therapies. While only 56.4% of the anti-CD20 group showed a detectable humoral response (compared to 93.6% in the group on no or other DMTs), nearly all of them—96.9%—mounted a successful T-cell response.

Quantitative T-Cell Superiority

Surprisingly, patients on anti-CD20 therapies did not just maintain a T-cell response; they exhibited a significantly stronger one. The anti-CD20 group showed T-cell counts (IFN-γ SFCs) that were over 400% higher than those not on any DMT. Statistically, anti-CD20 therapy was associated with a 1.36 higher log(IFN-γ SFC count) compared to other DMTs (p<0.001).

The Role of Timing and Drug Class

For patients on anti-CD20 medications, the probability of mounting a successful antibody response increased the longer the interval between their last drug infusion and their first vaccine dose.

In contrast, the small subset of patients on S1P modulators (fingolimod, n=3) appeared to have poor outcomes in both categories, showing diminished antibody and T-cell responses. This is likely due to the drug's mechanism of preventing immune cells from exiting the lymph nodes to circulate in the blood.

Discussion

The authors hypothesize that the robust T-cell response in B-cell depleted patients may be due to the removal of a "regulatory brake." Regulatory B cells normally help modulate the immune system; when these are depleted by anti-CD20 therapy, the T-cell response to a vaccine may be "unleashed," leading to the high SFC counts observed in this study.

Limitations and Future Directions

While these findings are encouraging, several questions remain:

  • Clinical Protection: It is currently unknown if a robust T-cell response alone, in the absence of antibodies, is sufficient to prevent infection or severe COVID-19.
  • Sample Size: The findings regarding S1P modulators require validation in larger cohorts.
  • Durability: As a cross-sectional study, it remains unclear how long this heightened T-cell response lasts or how it reacts to subsequent booster doses.

Conclusion

This research provides a critical "silver lining" for MS patients on B-cell depleting therapies. Even when commercial antibody tests return negative results, the cellular arm of the immune system appears to be highly active, potentially providing a vital layer of defense against SARS-CoV-2.

Summary updated

Abstract

We identified a robust T cell response in individuals on anti-CD20 therapies despite a reduced humoral response to SARS-CoV-2 vaccination. Follow up studies are needed to determine if this translates to protection against COVID-19 infection.
BibTeX
@misc{gadani2021discordant,
  author = {Sachin P. Gadani and Maria Reyes‐Mantilla and Larissa Jank and Samantha Harris and Morgan Douglas and Matthew D. Smith and Peter A. Calabresi and Ellen M. Mowry and Kathryn C. Fitzgerald and Pavan Bhargava},
  title = {{Discordant humoral and T cell immune responses to SARS-CoV-2 vaccination in people with multiple sclerosis on anti-CD20 therapy}},
  year = {2021},
  doi = {10.1101/2021.08.23.21262472},
  howpublished = {medRxiv},
}
Figure